



**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 70400

**Title:** Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 05464548

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Academic Research, Research Associate, Research Scientist

**Reviewer’s Country/Territory:** Iran

**Author’s Country/Territory:** China

**Manuscript submission date:** 2021-08-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-08-23 05:39

**Reviewer performed review:** 2021-08-23 07:28

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



<b>Peer-reviewer statements</b>	Peer-Review: [ <input type="checkbox"/> ] Anonymous [ <input checked="" type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

### SPECIFIC COMMENTS TO AUTHORS

Dear Authors, Thank you so much for preparation this rare case from prostate cancer. I read the paper in details and I found some points that I would share for your consideration;

1. These days, using the 68Ga-PSMA PET is highly recommended for rare cases in initial stages for finding small lesions around the prostate bed or extra-prostate LN metastasis. Therefore, conventional imaging such as CT or MRI is not recommended only for initial imaging or staging of the patients. In your case, however; you provided the historical info about the patient but it seems that medical imaging for this case is not under updated scans (PET/CT).
2. Regarding the developing of 177Lu-PSMA-617 for treatment planning of metastatic prostate cancer patients, I think you have to focus on the new tracers which are FDA approved. Please check the below link for checking the results about the same case that the authors prepared it very perfectly not only for the initial imaging but for following under 177Lu-PSMA-617 therapy (three or four cycle); <https://tech.snmjournals.org/content/jnmt/47/1/85.full.pdf>
3. With no specific symptoms in the early stage, CT scan or another conventional imaging cannot find active masses from the body. It seems sometimes you find the lesions in the lung as a metastatic site but you do not know about function of the lesion. So it is not perfect for only focusing on the structural imaging for final decision on the interpretation. In short, I could not finally have a clear decision on your case and in my opinion it is not ready to publish according the previous comments.
4. The images do not provide with good resolution and also the name of the patients must remove from the images without consent from patients. As an another point, please use the lung window for showing the



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**https://**[www.wjgnet.com](http://www.wjgnet.com)

involved masses. I kindly ask you please provide the more imaging data from the patient regarding the comments and then transfer to me for more discussion. Hope your case is ready for publishing in the valuable journal soon. Thanks.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 70400

**Title:** Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05464548

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Academic Research, Research Associate, Research Scientist

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-08-01

**Reviewer chosen by:** Ji-Hong Liu

**Reviewer accepted review:** 2021-11-24 12:09

**Reviewer performed review:** 2021-11-24 12:12

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear Authors, Thank you so much for your nice paper after final revision of the article. Hope we can hear more from your valuable team in the soonest future.  
Sincerely,